Comorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights From the HELIOS-B Trial [0.03%]
转甲状腺素蛋白淀粉样变性心肌病的共病负担：来自HELIOS-B试验的见解
Sarah M Birkhoelzer,Yasuhiro Hamatani,Karola S Jering et al.
Sarah M Birkhoelzer et al.
Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV: Insights From the CAVIAR Trial [0.03%]
高LDL-C和脂蛋白(a)通过CAVIAR试验修改Alirocumab对CAV的影响的见解
Kosei Terada,Kuniaki Takahashi,Kiran K Khush et al.
Kosei Terada et al.
In heart transplant recipients, alirocumab attenuated cardiac allograft vasculopathy progression only in patients with concomitantly elevated LDL-C and lipoprotein(a). Lipid phenotype–guided risk stratification may identify those most like...
Body Composition in Heart Failure: A Magnetic Resonance Imaging and Dual X-Ray Absorptiometry Assessment in the UK Biobank Study [0.03%]
英国生物样本库研究中的心力衰竭体组成：磁共振成像和双X线吸收测定法评估结果
Javed Butler,Francesco Fioretti,Stefan D Anker et al.
Javed Butler et al.
Background: Metabolic and musculoskeletal abnormalities in patients with heart failure (HF) may not be fully captured by body mass index. Objectives: ...
Disparities in Listing With a Durable Left Ventricular Assist Device After 2018 Heart Allocation Policy Change [0.03%]
2018年心脏分配政策变更后左心室辅助装置患者的注册差异
Alexander Z Wang,Molly H White,Nikhil Narang et al.
Alexander Z Wang et al.
Background: Following the 2018 U.S. heart allocation policy change, transplant centers became less likely to use a bridge-to-transplant (BTT) durable left ventricular assist device (LVAD) strategy. Previous work has shown...
Sounok Sen,Tariq Ahmad
Sounok Sen
National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction [0.03%]
射血分数降低的心力衰竭患者最佳应用指南指导的药物治疗的全国影响
Mohammad Keykhaei,Alexander T Sandhu,Priscilla Y Hsue et al.
Mohammad Keykhaei et al.
Background: Despite robust evidence that quadruple guideline-directed medical therapy (GDMT), comprising angiotensin receptor-neprilysin inhibitors (ARNIs), evidence-based beta-blockers, mineralocorticoid receptor antagon...
Patient-Facing Alerts in Heart Failure: From More Information to Better Action [0.03%]
心力衰竭患者的提醒：从提供更多息到促进更好行动
Kannu Bansal,F Perry Wilson
Kannu Bansal
Beyond Survival: The Functional and Quality of Life Impact of Cardiogenic Shock [0.03%]
生存之外：心脏骤停的功能和生活质量影响
Krishna K Patel,Laura P Gelfman
Krishna K Patel
Dapagliflozin in Patients With Heart Failure Across the Care Spectrum: A Meta-Analysis of DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68 [0.03%]
达格列净在心血管照护谱系中心力衰竭患者的疗效：DAPA-HF、DELIVER和DAPA ACT HF-TIMI 68研究的Meta分析
David D Berg,Muthiah Vaduganathan,Kieran F Docherty et al.
David D Berg et al.
Amir Kazory,Abhilash Koratala
Amir Kazory